<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT02256475</url>
  </required_header>
  <id_info>
    <org_study_id>NBI-98854-1403</org_study_id>
    <nct_id>NCT02256475</nct_id>
  </id_info>
  <brief_title>Safety, Pharmacokinetics, and Pharmacodynamics of NBI-98854 in Children and Adolescents With Tourette Syndrome</brief_title>
  <acronym>T-FORCE</acronym>
  <official_title>A Phase 1b, Open-Label, Multiple-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NBI-98854 in Children and Adolescents With Tourette Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Neurocrine Biosciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Neurocrine Biosciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1b, open-label, multiple-dose study of the safety, pharmacokinetics (PK), and&#xD;
      pharmacodynamics (PD) of NBI-98854 in a total of 36 pediatric subjects with Tourette syndrome&#xD;
      (TS). The study will be conducted in approximately 18 male and female children (6 to 11 years&#xD;
      of age) and approximately 18 male and female adolescents (12 to 18 years of age). Both age&#xD;
      groups will be divided equally into 3 dosing cohorts with 6 subjects each. Ascending doses&#xD;
      will be evaluated as part of a staggered-cohort design. Study drug will be administered in&#xD;
      each cohort for 14 consecutive days.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2014</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">November 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with adverse events following dosing with NBI-98854</measure>
    <time_frame>Up to 21 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under Curve (AUC) of NBI-98854 and its metabolites following repeated daily doses of NBI-98854</measure>
    <time_frame>Day 1: predose, 0.5, 1, 2, 4, 6, 8, 12, 24 hours post-dose; Day 14: predose, 0.5, 1, 2, 4, 6, 8, 12, 24, 72, 120, 168 hours postdose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Assessment of tic behaviors associated with TS using the Yale Global Tic Severity Scale (YGTSS)</measure>
    <time_frame>Days 1, 7, 14, and 21</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assessment of tic behaviors associated with TS using the Rush Video-based Tic Rating Scale (RTRS)</measure>
    <time_frame>Days 1, 7, 14, and 21</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quantification of the premonitory urge phenomena associated with tics using the Premonitory Urge for Tics Scale (PUTS)</measure>
    <time_frame>Days 1, 7, 14, and 21</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Global Impression of Tourette Syndrome (CGI-TS)</measure>
    <time_frame>Days 1, 7, 14, and 21</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CogState computerized test to assess cognitive function</measure>
    <time_frame>Day 1 at predose, 2.5 and 8 hours postdose; Day 14 at 8 hours postdose</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Tourette Syndrome</condition>
  <arm_group>
    <arm_group_label>Adolescents Dose Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fixed dose of NBI-98854 administered once daily at 0800 for 14 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Adolescents Dose Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fixed dose of NBI-98854 administered once daily at 0800 for 14 days. Dosing will not commence until all safety and PK results from the adolescent dose group 1 have been reviewed to ensure there are no safety concerns and that maximum tolerated dose (MTD) has not been reached.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Adolescents Dose Group 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fixed dose of NBI-98854 administered once daily at 0800 for 14 days. Dosing will not commence until all safety and PK results from the adolescent dose group 2 have been reviewed to ensure there are no safety concerns and that MTD has not been reached.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Children Dose Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fixed dose of NBI-98854 administered once daily at 0800 for 14 days. Dosing will not commence until all safety and PK results from the adolescent dose group 1 have been reviewed to ensure there are no safety concerns and that MTD has not been reached.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Children Dose Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fixed dose of NBI-98854 administered once daily at 0800 for 14 days. Dosing will not commence until all safety and PK results from the children dose group 1 have been reviewed to ensure there are no safety concerns and that MTD has not been reached.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Children Dose Group 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fixed dose of NBI-98854 administered once daily at 0800 for 14 days. Dosing will not commence until all safety and PK results from the children dose group 2 have been reviewed to ensure there are no safety concerns and that MTD has not been reached.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NBI-98854</intervention_name>
    <arm_group_label>Adolescents Dose Group 1</arm_group_label>
    <arm_group_label>Adolescents Dose Group 2</arm_group_label>
    <arm_group_label>Adolescents Dose Group 3</arm_group_label>
    <arm_group_label>Children Dose Group 1</arm_group_label>
    <arm_group_label>Children Dose Group 2</arm_group_label>
    <arm_group_label>Children Dose Group 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Have documentation of written informed consent, or written and witnessed assent from&#xD;
             the subject and written informed consent from the subject's parent or legal guardian.&#xD;
&#xD;
          2. Be in good general health.&#xD;
&#xD;
          3. Have a Diagnostic and Statistical Manual of Mental Disorders diagnosis of Tourette&#xD;
             Syndrome (DSM-IV or -V).&#xD;
&#xD;
          4. Have TS symptoms that impair school, occupational, and/or social function.&#xD;
&#xD;
          5. If medications are being used to treat TS symptoms, must be on stable doses of these&#xD;
             medications for a minimum of 30 days before baseline (Day -1), and the medication&#xD;
             regimen is expected to remain stable throughout the study period. The use of&#xD;
             tetrabenazine to treat TS symptoms is prohibited.&#xD;
&#xD;
          6. Subjects of childbearing potential who do not practice total abstinence must be&#xD;
             instructed on the proper use of barrier methods of contraception and agree to use&#xD;
             hormonal or two forms of nonhormonal contraception consistently from screening until&#xD;
             30 days after the last dose of study drug.&#xD;
&#xD;
          7. Adolescent subjects (12 to 18 years of age) must have a negative urine drug screen for&#xD;
             amphetamines, barbiturates, benzodiazepine, phencyclidine, cocaine, opiates, or&#xD;
             cannabinoids. Subjects who are on stable doses of prescribed benzodiazepines, opiates,&#xD;
             or psychostimulants are allowed to participate in the study.&#xD;
&#xD;
          8. Adolescent subjects (12 to 18 years of age) must have a negative alcohol breath test.&#xD;
&#xD;
          9. Be willing and able to adhere to the study regimen and study procedures described in&#xD;
             the protocol and informed consent/assent forms, including all requirements at the&#xD;
             study center and return for the follow-up visit.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Have an unstable medical condition or chronic disease.&#xD;
&#xD;
          2. Had a medically significant illness within 30 days of screening.&#xD;
&#xD;
          3. Excessive use of tobacco and/or nicotine-containing products.&#xD;
&#xD;
          4. Have a history of substance (drug) dependence or substance or alcohol abuse.&#xD;
&#xD;
          5. Are currently pregnant or lactating.&#xD;
&#xD;
          6. Have a known history of neuroleptic malignant syndrome.&#xD;
&#xD;
          7. Have a known history of long QT syndrome or cardiac tachy-arrhythmia.&#xD;
&#xD;
          8. Have a cancer diagnosis within 3 years prior to screening, with the exception of&#xD;
             localized skin cancer or carcinoma in situ of the cervix.&#xD;
&#xD;
          9. Have received an investigational drug within 30 days before screening or plan to use&#xD;
             an investigational drug (other than NBI-98854) during the study.&#xD;
&#xD;
         10. Have a significant risk of suicidal or violent behavior.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chris O'Brien, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Neurocrine Biosciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kissimmee</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>St. Petersburg</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Naperville</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lincoln</city>
        <state>Nebraska</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Petersburg</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kirkland</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2016</verification_date>
  <study_first_submitted>September 23, 2014</study_first_submitted>
  <study_first_submitted_qc>September 30, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 3, 2014</study_first_posted>
  <last_update_submitted>January 5, 2016</last_update_submitted>
  <last_update_submitted_qc>January 5, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 7, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tourette Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT02256475
org study id: NBI-98854-1403
nct id: NCT02256475
lead sponsor: 
has dmc: No
This is a Phase 1b, open-label, multiple-dose study of the safety, pharmacokinetics (PK), and
      pharmacodynamics (PD) of NBI-98854 in a total of 36 pediatric subjects with Tourette syndrome
      (TS). The study will be conducted in approximately 18 male and female children (6 to 11 years
      of age) and approximately 18 male and female adolescents (12 to 18 years of age). Both age
      groups will be divided equally into 3 dosing cohorts with 6 subjects each. Ascending doses
      will be evaluated as part of a staggered-cohort design. Study drug will be administered in
      each cohort for 14 consecutive days.
allocation: Non-Randomized
intervention model: Parallel Assignment
primary purpose: Basic Science
masking: None (Open Label)
measure: Number of participants with adverse events following dosing with NBI-98854
time frame: Up to 21 days
measure: Area Under Curve (AUC) of NBI-98854 and its metabolites following repeated daily doses of NBI-98854
time frame: Day 1: predose, 0.5, 1, 2, 4, 6, 8, 12, 24 hours post-dose; Day 14: predose, 0.5, 1, 2, 4, 6, 8, 12, 24, 72, 120, 168 hours postdose
measure: Assessment of tic behaviors associated with TS using the Yale Global Tic Severity Scale (YGTSS)
time frame: Days 1, 7, 14, and 21
measure: Assessment of tic behaviors associated with TS using the Rush Video-based Tic Rating Scale (RTRS)
time frame: Days 1, 7, 14, and 21
measure: Quantification of the premonitory urge phenomena associated with tics using the Premonitory Urge for Tics Scale (PUTS)
time frame: Days 1, 7, 14, and 21
measure: Clinical Global Impression of Tourette Syndrome (CGI-TS)
time frame: Days 1, 7, 14, and 21
measure: CogState computerized test to assess cognitive function
time frame: Day 1 at predose, 2.5 and 8 hours postdose; Day 14 at 8 hours postdose
arm group label: Adolescents Dose Group 1
arm group type: Experimental
description: Fixed dose of NBI-98854 administered once daily at 0800 for 14 days.
arm group label: Adolescents Dose Group 2
arm group type: Experimental
description: Fixed dose of NBI-98854 administered once daily at 0800 for 14 days. Dosing will not commence until all safety and PK results from the adolescent dose group 1 have been reviewed to ensure there are no safety concerns and that maximum tolerated dose (MTD) has not been reached.
arm group label: Adolescents Dose Group 3
arm group type: Experimental
description: Fixed dose of NBI-98854 administered once daily at 0800 for 14 days. Dosing will not commence until all safety and PK results from the adolescent dose group 2 have been reviewed to ensure there are no safety concerns and that MTD has not been reached.
arm group label: Children Dose Group 1
arm group type: Experimental
description: Fixed dose of NBI-98854 administered once daily at 0800 for 14 days. Dosing will not commence until all safety and PK results from the adolescent dose group 1 have been reviewed to ensure there are no safety concerns and that MTD has not been reached.
arm group label: Children Dose Group 2
arm group type: Experimental
description: Fixed dose of NBI-98854 administered once daily at 0800 for 14 days. Dosing will not commence until all safety and PK results from the children dose group 1 have been reviewed to ensure there are no safety concerns and that MTD has not been reached.
arm group label: Children Dose Group 3
arm group type: Experimental
description: Fixed dose of NBI-98854 administered once daily at 0800 for 14 days. Dosing will not commence until all safety and PK results from the children dose group 2 have been reviewed to ensure there are no safety concerns and that MTD has not been reached.
intervention type: Drug
intervention name: NBI-98854
arm group label: Adolescents Dose Group 1
arm group label: Adolescents Dose Group 2
arm group label: Adolescents Dose Group 3
arm group label: Children Dose Group 1
arm group label: Children Dose Group 2
arm group label: Children Dose Group 3
criteria: 
gender: All
minimum age: 6 Years
maximum age: 18 Years
healthy volunteers: No
last name: Chris O'Brien, MD
role: Principal Investigator
affiliation: Neurocrine Biosciences
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
country: United States
responsible party type: Sponsor
mesh term: Tourette Syndrome
mesh term: Syndrome